Skip to content
Strength & muscleEvidence review3 min read

About 10% of healthy older adults worldwide have sarcopenia, with large measurement differences

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies. · Journal of diabetes and metabolic disorders · 2017 · Original paper ↗

Key takeaway

Pooling 35 articles and 58404 adults aged 60 or older, the estimated sarcopenia prevalence was 10% in men (95% CI 8-12%) and 10% in women (95% CI 8-13%). Prevalence was higher in non-Asian than Asian people when muscle was measured by bioelectrical impedance, and the abstract notes the studies used different tools and regions.

Study design

Evidence review

Reading basis

Published abstract

Reading focus

Design & applicability

The research question

Sarcopenia, age-related loss of muscle mass and function, is a major problem in older people, but prevalence estimates differ widely between studies. The authors pooled population-based studies to estimate how common sarcopenia is in men and women in different regions of the world.

Who and how

Systematic review and meta-analysis. MEDLINE (via PubMed), SCOPUS and Web of Science were searched between January 2009 and December 2016 for population-based studies reporting sarcopenia prevalence in healthy adults aged 60 or older, using the EWGSOP, IWGS or AWGS definitions (low muscle mass plus low handgrip strength or slow gait speed). A random-effects model estimated prevalence, with sex-specific rates and 95% CI from the Binomial Exact Method, and subgroup analysis to explore heterogeneity. 35 articles with 58404 people were included.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Estimated prevalence of sarcopenia was 10% in men (95% CI 8-12%) and 10% in women (95% CI 8-13%).
  2. 2
    It was higher in non-Asian than Asian individuals for both sexes, especially when muscle mass was measured by bioelectrical impedance analysis (BIA): 19% versus 10% in men and 20% versus 11% in women.
  3. 3
    The authors conclude that a substantial share of older people, even healthy ones, have sarcopenia, despite differences between studies in diagnostic tools and regions.

Limits & uncertainty

  1. 1
    Studies used different consensus definitions and different tools for measuring muscle mass, which makes pooled numbers depend on method; the authors cite this heterogeneity.
  2. 2
    Only healthy adults aged 60 or older were included, so the figures may not describe frailer older people or institutionalized groups.
  3. 3
    The abstract does not report the pooled heterogeneity statistics, so how much the results vary across studies is unclear.
  4. 4
    The Asian versus non-Asian comparison is a subgroup analysis and is confounded by the measurement method used in each region.

What to take from it

Roughly one in ten healthy older adults meets the definition of sarcopenia, so it is common but not universal. Which method is used to measure muscle changes the answer. Strength and mobility problems are worth discussing with a clinician, since early diagnosis may help limit adverse outcomes.

Reading your own data

Consumer scales with BIA give rough muscle estimates and vary by device, hydration and time of day. If you track them, use the same scale at the same time under the same conditions and watch the trend. Handgrip strength and usual walking speed are the other components of the diagnosis.

How to read this evidence

Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Background

Sarcopenia, an age-related decline in muscle mass and function, is one of the most important health problems in elderly with a high rate of adverse outcomes. However, several studies have investigated the prevalence of sarcopenia in the world, the results have been inconsistent. The current systematic review and meta- analysis study was conducted to estimate the overall prevalence of sarcopenia in both genders in different regions of the world.

Methods

Electronic databases, including MEDLINE (via PubMed), SCOPUS and Web of Science were searched between January 2009 and December 2016. The population- based studies that reported the prevalence of sarcopenia in healthy adults aged ≥ 60 years using the European Working Group on Sarcopenia in Older People (EWGSOP), the International Working Group on Sarcopenia (IWGS) and Asian Working Group for Sarcopenia (AWGS) definitions, were selected. According to these consensual definitions, sarcopenia was defined by presence of low muscle mass (adjusted appendicular muscle mass for height) and muscle strength (handgrip strength) or physical performance (the usual gait speed). The random effect model was used for estimation the prevalence of sarcopenia. The sex-specific prevalence of sarcopenia and 95% confidence interval (CI) were calculated using the Binomial Exact Method. Heterogeneity was assessed by subgroup analysis.

Results

Thirty- five articles met our inclusion criteria, with a total of 58404 individuals. The overall estimates of prevalence was 10% (95% CI: 8-12%) in men and 10% (95% CI: 8-13%) in women, respectively. The prevalence was higher among non- Asian than Asian individuals in both genders especially, when the Bio-electrical Impedance Analysis (BIA) was used to measure muscle mass (19% vs 10% in men; 20% vs 11% in women).

Conclusion

Despite the differences encountered between the studies, regarding diagnostic tools used to measure of muscle mass and different regions of the world for estimating parameters of sarcopenia, present systematic review revealed that a substantial proportion of the old people has sarcopenia, even in healthy populations. However, sarcopenia is as a consequence of the aging progress, early diagnosis can prevent some adverse outcomes.

Sources & attribution

Prevalence of sarcopenia in the world: a systematic review and meta- analysis of general population studies.

Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R.

Journal of diabetes and metabolic disorders · 2017-05-16

DOI: 10.1186/s40200-017-0302-x ↗PubMed · 28523252 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Overview of reviews

ACSM review of 137 reviews: resistance training works, and few programme details matter

The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.

Medicine & Science in Sports & Exercise

In-depth explainersRead study →
·Trial meta-analysis

Nearly every resistance training plan beat no exercise; heavy loads led for strength

In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.

British Journal of Sports Medicine

In-depth explainersRead study →
·Observational meta-analysis

Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes

Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.

British Journal of Sports Medicine

In-depth explainersRead study →
·Trial meta-analysis

Protein supplements and weight training: small extra gains, smaller in older adults

Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.

British Journal of Sports Medicine

In-depth explainersRead study →
Strength & muscle →